Loading
In HER2CLIMB-05, adding the brain-penetrant pill tucatinib to maintenance antibodies after first-line chemotherapy delayed progression by more than eight months.
HER2CLIMB-05, trial NCT05132582 sponsored by Pfizer and reported at SABCS 2025, showed that adding the brain-penetrant tablet tucatinib to maintenance trastuzumab and pertuzumab after first-line induction chemotherapy for HER2-positive metastatic breast cancer delayed progression by more than eight months. It randomised 654 women to tucatinib or placebo with the two antibodies after taxane induction and met its primary progression-free survival endpoint with a benefit consistent across brain metastasis and hormone receptor subgroups, offering a chemotherapy-free intensification of maintenance. OnCo links it to tucatinib, trastuzumab and pertuzumab, and the result is consistent with HER2CLIMB. Overall survival is pending, and its place against first-line trastuzumab deruxtecan plus pertuzumab from DESTINY-Breast09 is unsettled, which is the open question. Tucatinib has its own page.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
654 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Tucatinib + trastuzumab + pertuzumab | - | 24.9 months | 0.641 | <0.0001 | link |
| Placebo + trastuzumab + pertuzumab | - | 16.3 months |
Shares HER2 tyrosine kinase inhibitors, HER2-positive breast cancer with brain metastases, Tucatinib, Pfizer (incl. Seagen).
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Pfizer (incl. Seagen), Trastuzumab.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Pfizer (incl. Seagen), Trastuzumab.
Shares HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab, HER2-positive breast cancer.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Trastuzumab, Small-molecule kinase inhibitors.
Shares Tucatinib, Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Pfizer (incl. Seagen), HER2-positive breast cancer.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Trastuzumab, Small-molecule kinase inhibitors.